CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Recombinant Salmon Calcitonin (rsCT) +3 moredrug
Likely dose
Nasal Spray 200 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00620854
NCT00620854Phase 2Completed
CompareCT.gov

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

Tarsa Therapeutics, Inc.·interventional·Posted Feb 22, 2008·Updated Feb 1, 2012

In Brief

A Phase 2 clinical trial evaluating Recombinant Salmon Calcitonin (rsCT), Oral Tablet, and 1 other intervention for Osteoporosis. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 22, 2008
Enrollment StartFeb 1, 2008
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.4 years ago

Interventions

Recombinant Salmon Calcitonin (rsCT)drug

Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.

Oral Tabletdrug

0.15 mgs recombinant salmon calcitonin, single oral dose

Oral Tabletdrug

0.2mgs recombinant salmon calcitonin, single oral tablet

Nasal Spraydrug

200 IU recombinant salmon calcitonin, single intranasal spray